<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496483</url>
  </required_header>
  <id_info>
    <org_study_id>LCP-Tacro 2011</org_study_id>
    <nct_id>NCT00496483</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial and Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A three sequence, open-label, multi-center, prospective, study in stable kidney transplant
      patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of
      LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A three sequence, open-label, multi-center, prospective, study in stable kidney transplant
      patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of
      LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.

      Stable kidney transplant patients who fulfill all I/E criteria will be enrolled and kept on
      Prograf for 7 days. Following a 24-hour PK study on Day 7 to determine pharmacokinetics for
      Prograf, all patients will be converted to once daily LCP-Tacro for 7 days with no dose
      changes allowed. On Day 14 and Day 21 a 24-hour LCP-Tacro PK study will be performed. On Day
      22 patients will be converted back to their original twice daily dose of Prograf for a safety
      follow-up period of 30 days ending with a safety assessment on day 53.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Steady State Tacrolimus Trough Levels (C24).</measure>
    <time_frame>7 days</time_frame>
    <description>Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</measure>
    <time_frame>7 days</time_frame>
    <description>Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).</measure>
    <time_frame>21 days</time_frame>
    <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</measure>
    <time_frame>21 days</time_frame>
    <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 21.</measure>
    <time_frame>21 days</time_frame>
    <description>Cmax and Cavg was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 21.</measure>
    <time_frame>21 days</time_frame>
    <description>Tmax was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 21.</measure>
    <time_frame>21 days</time_frame>
    <description>Degree og fluctuation and degree of swing was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 7.</measure>
    <time_frame>7 days</time_frame>
    <description>Cmax and Cavg was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 7.</measure>
    <time_frame>7 days</time_frame>
    <description>Tmax was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 7.</measure>
    <time_frame>7 days</time_frame>
    <description>Degree og fluctuation and degree of swing was measured as baseline at day 7 (Cmin was measured as part of the primary outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>52 days</time_frame>
    <description>A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>LCP-Tacro (tacrolimus)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCP Tacro (tacrolimus)</intervention_name>
    <description>Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.</description>
    <arm_group_label>LCP-Tacro (tacrolimus)</arm_group_label>
    <other_name>tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.</description>
    <arm_group_label>LCP-Tacro (tacrolimus)</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-65 years of age who are recipients of a renal transplant at least 6
             months prior to enrollment

          -  Patients on oral Prograf therapy as part of their maintenance immunosuppression
             therapy, with stable doses and trough levels of tacrolimus of 7-12 ng/mL for at least
             two weeks prior to enrollment.

          -  Patients maintained on concurrent immunosuppression with mycophenolate mofetil (MMF,
             CellCept) or mycophenolic acid delayed-release tablets (Myfortic), with stable doses
             for at least two weeks prior to enrollment

          -  Patients with serum creatinine &lt; 2.0mg/dL prior to enrollment

          -  Able to swallow study medication

          -  Patients capable of understanding the purposes and risks of the study, who can give
             written informed consent and who are willing to participate in and comply with the
             study

          -  Women of childbearing potential must have a negative serum pregnancy test within seven
             days prior to receiving study medication

          -  Patients who successfully pass a drug screen

        Exclusion Criteria:

          -  Recipients of any transplanted organ other than a kidney

          -  White blood cell count &lt; 2.8 x 10^9 /L

          -  Patients who are receiving a total dose of Prograf for 24 hours &lt; 3mg

          -  Patients unable or unwilling to provide informed consent

          -  Pregnant or nursing women

          -  Patients with reproductive potential who are unwilling/unable to use a double barrier
             method of contraception

          -  Administration of other investigational agent in the three months prior to enrollment

          -  Patient receiving any drug interfering with tacrolimus metabolism

          -  Patients who have taken sirolimus within the past three months prior to screening

          -  Patient with an episode of acute cellular requiring antibody therapy within the 6
             months prior to enrollment

          -  Patient treated for acute cellular rejection within the 30 days prior to enrollment

          -  Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV
             antibody) donor kidney

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except basal or non-metastatic squamous cell carcinoma of the skin that has been
             treated successfully

          -  Patient has uncontrolled concomitant infection, a systemic infection requiring
             treatment, or any other unstable medical condition that could interfere with the study
             objectives

          -  Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal
             disorder that may affect the absorption of tacrolimus

          -  Patient will require therapy with any immunosuppressive agent other than those
             prescribed in the study

          -  Patient has a known hypersensitivity to corticosteroids, mycophenolate mofetil,
             mycophenolic acid or tacrolimus

          -  Patient has any form of current substance abuse, psychiatric disorder or a condition
             that, in the opinion of the Investigator, may invalidate communication with the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Glicklich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Veloxis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <results_first_submitted>May 29, 2014</results_first_submitted>
  <results_first_submitted_qc>June 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Kidney Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCP-Tacro</title>
          <description>All Patients received Prograf for 7 days, then all patients were converted to once daily LCP-Tacro for 14 days. One dose adjustment up or down 25% was permitted on Day 15.
On Day 22 patients were converted back to their original twice daily dose of Prograf for a safety follow-up period of 30 days.
LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCP-Tacro</title>
          <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 21.</title>
        <description>Cmax and Cavg was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>21 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 21.</title>
          <description>Cmax and Cavg was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.94" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 21.</title>
        <description>Tmax was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>21 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 21.</title>
          <description>Tmax was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="1.50" upper_limit="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 21.</title>
        <description>Degree og fluctuation and degree of swing was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>21 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
Arithmetic mean and standard deviation is given below.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 21.</title>
          <description>Degree og fluctuation and degree of swing was measured at day 21 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
Arithmetic mean and standard deviation is given below.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fluctuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.04" spread="50.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.07" spread="89.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Steady State Tacrolimus Trough Levels (C24).</title>
        <description>Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.</description>
        <time_frame>7 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>Prograf</title>
            <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally twice daily, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Steady State Tacrolimus Trough Levels (C24).</title>
          <description>Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</title>
        <description>Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.</description>
        <time_frame>7 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>Prograf</title>
            <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</title>
          <description>Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro.</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.82" spread="55.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).</title>
        <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.</description>
        <time_frame>21 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).</title>
          <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</title>
        <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).</description>
        <time_frame>21 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).</title>
          <description>Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.
The arithmetic mean and standard deviation is given.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.03" spread="68.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 7.</title>
        <description>Cmax and Cavg was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>7 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
        <group_list>
          <group group_id="O1">
            <title>Prograf</title>
            <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Cmax and Cavg) Was Measured at Day 7.</title>
          <description>Cmax and Cavg was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
The arithmetic mean and standard deviation is given.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.14" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cavg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 7.</title>
        <description>Tmax was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>7 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Prograf</title>
            <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Tmax) Was Measured at Day 7.</title>
          <description>Tmax was measured at baseline day 7 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate. Another patient discontinued before the Day 21 visit.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="0.50" upper_limit="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 7.</title>
        <description>Degree og fluctuation and degree of swing was measured as baseline at day 7 (Cmin was measured as part of the primary outcome).</description>
        <time_frame>7 days</time_frame>
        <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
Arithmetic mean and standard deviation is given below.</population>
        <group_list>
          <group group_id="O1">
            <title>Prograf</title>
            <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Pharmacokinetics (Fluctuation and Swing) Was Measured at Day 7.</title>
          <description>Degree og fluctuation and degree of swing was measured as baseline at day 7 (Cmin was measured as part of the primary outcome).</description>
          <population>48 completed treatment with LCP-Tacro but one patient was excluded from the PP analysis due to inappropriate conversion rate.
Arithmetic mean and standard deviation is given below.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fluctuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.41" spread="57.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.55" spread="93.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Evaluation</title>
        <description>A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.</description>
        <time_frame>52 days</time_frame>
        <population>All enrolled patients are included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>LCP-Tacro</title>
            <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Evaluation</title>
          <description>A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.</description>
          <population>All enrolled patients are included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCP-Tacro</title>
          <description>LCP-Tacro 1 mg, 2 mg and 5 mg tablets administered orally QD, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.
60 patients were enrolled into the study, but only 51 were dosed with LCP-Tacro.</description>
        </group>
        <group group_id="E2">
          <title>Prograf</title>
          <description>Prograf 0.5 mg, 1 mg and 5 mg capsules administered orally twice daily, dosing per conversion algorithm to maintain tacrolimus trough concentrations between 7 to 12 ng/mL.
60 patients were entrolled into the study and one withdrew consent right after screening. Therefore 59 patients are inlcuded in the ITT safety set.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctuvitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gatroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urinary casts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dsypnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study is a multicenter collaborative investigation and the clinical trial results are to be published as a collaborative manuscript. Authorship will reflect varying levels of individual contribution to the study by the individual PI’s.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christina Sylvest, Sr VP, Global Clinical Development and Operations</name_or_title>
      <organization>Veloxis A/S</organization>
      <phone>+45 20553877</phone>
      <email>csy@veloxis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

